Search PubMed⌕ Search

Biomedical subjects

S Ono

Publications and source records attributed to S Ono.

At least 793 records · Page 44Linked to original sources
PubMed1983

Studies on the riboflavin-binding capacity of the rat lens.

Previous studies have confirmed that riboflavin-binding protein exists in the rat lens. We now provide evidence that riboflavin-binding was the same at 4 degrees C and 37 degrees C, that there was a saturation curve when 14C-riboflavin was the substrate, that there was an ATP-dependent increase of binding, and that EGTA and PCMB did not affect riboflavin binding while it was decreased upon protease digestion and upon the addition of heavy metal compounds. Furthermore, binding was lower in the lenses of rats which had been fed a B2-deficient diet for 8 weeks than in animals receiving this diet for 4 weeks. When 14C-B2 butyrate rather than 14C-riboflavin was the substrate, binding was considerably higher in the lens homogenate and the single whole lens. Partial purification of riboflavin-binding protein using flavinyl agar-bead affinity chromatography confirmed the presence of a trace amount of riboflavin-binding protein in the bovine lens. Our results suggest that changes in the riboflavin-binding capacity of the lens may play a role in the regulation of absorption, transport and metabolism of riboflavin in the lens associated with the synthesis of ester forms of riboflavin.

Animals↗
PubMed1983

[Clinical study on ureterosigmoidostomy].

Clinical studies were made of 60 patients who had undergone ureterosigmoidostomy at our department. The 45 men and 15 women ranged from 35 to 73 years old, with a mean of 59.2 years. Ureterosigmoidanastomosis was performed using the modified Coffey II technique in this series. Bladder tumor was the reason for the operation in 55 cases, uterine cancer in 2, contracted bladder in 1, vesicovaginal fistula in 1 and urethral stricture in 1. In the excretory pyelogram one month after the operation, normal findings and slight hydronephrosis were observed in 37% and 63% of the patients, respectively. However, the pyelogram 6 months after the operation demonstrated normal findings in 61% of the patients, slight hydronephrosis in 34% and moderate hydronephrosis in 5%. None of them showed severe hydronephrosis. Slightly increased BUN level (less than 30 mg/dl) was seen in 15 out of 45 patients (32%) at one year after ureterosigmoidostomy. However, serum creatinine level was not above normal throughout the postoperative course. Although postoperative hyperchloremia was appreciably detected, it was easily managed by the administration of sodium bicarbonate. Serum sodium and potassium levels remained stationary. Of 35 patients observed for more than one year after operation, 11 patients (31%) had developed fever due probably to pyelonephritis, but sigmoidography failed to demonstrate any ureteral reflux. Either urinary or fecal fistula, a complication in the early postoperative period, occurred in 10 patients (17%). One of these patients died. Five patients were cured by conservative treatment. The remaining 4 patients underwent surgical treatment that was ureterocutaneostomy , nephrectomy, or colostomy.(ABSTRACT TRUNCATED AT 250 WORDS)

Adult↗
PubMed1983

[Surveillance colonoscopy after ureterosigmoidostomy].

Twenty-two patients underwent surveillance colonoscopy for 2 to 54 months (average, 22 months) after ureterosigmoidostomy. The distance between site of ureterocolonic anastomosis and anal verge ranged from 13 to 30 cm (average, 18.3 cm) in right side and from 20 to 37 cm (average, 29.5 cm) in left side. The form of implanted site could be classified into 3 types which were flat, sessile and pedunculated types. Endoscopic biopsies performed on eleven polyp-like regions of ureterocolonic anastomosis revealed inflammation in 10 cases (90%) and adenoma without malignancy in one case (10%). The mucosa more than 5 cm away from implanted site showed findings of inflammation without constitutional abnormality in more than 60% of all patients. The periodical surveillance colonoscopy at intervals of approximately one year seemed to be useful for early detection of the tumors of the colon after ureterosigmoidostomy.

Adult↗
PubMed1982

The preparation of puromycin antibody and its use in enzyme immunoassay for the quantification using beta-D-galactosidase as a label.

An antibody specific for puromycin (PU) was prepared by immunization of rabbits with a PU conjugate of bovine serum albumin, which was newly synthesized by coupling PU to mercaptosuccinylated bovine serum albumin via a cross-linker, N-(gamma-maleimidobutyryloxy)succinimide. Enzyme labeling of PU was performed using beta-D-galactosidase [EC 3.2.1.23] via N-(m-maleimidobenzoyloxy) succinimide. An ultrasensitive and specific enzyme immunoassay for PU was developed utilizing these reagents by a double antibody technique. The standard curve of the assay was linear in the range of 2 pg to 100 pg, and the lower limit of detection was 28.2 pm (2 pg/tube); so the enzyme immunoassay was found to be approximately 326,000 times more sensitive than a microbiological assay. Further, the enzyme immunoassay is free from interference by any purine or pyrimidine analogs, or by other drugs commonly used for the inhibition of protein synthesis. Using this assay, drug levels were easily determined in rat tissue following PU administration. Since PU is extensively available as an inhibitor of protein synthesis, the enzyme immunoassay should provide useful tool for developing biochemical and toxicity studies of PU.

Animals↗
PubMed1982

Insulin releasing action of 2-[2-(4,5-dihydro-1H-imadazol-2-yl)-1-phenylethyl] pyridine dihydrochloride sesquihydrate (DG-5128), a new, orally effective hypoglycaemic agent.

2-[2-(4,5-dihydro-1H-imidazol-2-yl)-1-phenylethyl] pyridine dihydrochloride sesquilhydrate (DG-5128) is a new orally effective hypoglycaemic agent structurally unrelated to the known hypoglycaemics. DG-5128 was found to decrease blood glucose levels by stimulating insulin release, like the sulphonylurea hypoglycaemics. However, the study with the rat Langerhans islets in vitro indicated a great difference in mode of stimulation of insulin release between DG-5128 and a sulphonylurea hypoglycaemic, tolbutamide. DG-5128 significantly reversed alpha-adrenergic inhibition of the glucose-primed insulin release from the islets, while tolbutamide did not. From the comparison with the effects of phentolamine, yohimbine and prazosine, DG-5128 was strongly suggested to stimulate the glucose-primed insulin release through antagonizing at alpha 2-adrenoreceptors on the B cells.

Administration, Oral↗
PubMed1982

[Evaluation of regional wall motion of the left ventricle before and after nitroglycerin administration in patients with ischemic heart disease: comparison between two-dimensional echocardiograms and coronary angiograms].

Effects of nitroglycerin (NTG) on segmental wall motion and pump function of the left ventricle (LV) were studied in 19 patients with ischemic heart disease (IHD) and 10 normal controls by two-dimensional echocardiography (2DE) and coronary arteriography (CAG). Short-axis cross-sectional images of the LV at the mitral valve, papillary muscles and the apex were recorded and subdivided into quadrants at each level. The center of gravity of the end-diastolic LV cavity and the axis intersecting this point and the right side of the posterior end of the interventricular septum were used as the reference point and line. The areas of whole sections and of each quadrant at end-diastole (Ad) and end-systole (As) were measured by the computer. Regional contractility and pump function of the LV were evaluated by (Ad-As)/Ad and (Ad-As) of quadrants and sections. The results were as follows: Blood pressure (BP), Ad and (Ad-As) of sections significantly decreased after NTG administration. (Ad-As)/Ad of the sections with normal wall motion showed no significant change after NTG. (Ad-As)/Ad of the quadrants with hypokinetic segmental wall motion showed a tendency to increase after NTG in contrast with the normal quadrants which showed no significant change. CAG findings and hemodynamic parameters in patients who showed a significant increase in (Ad-As)/Ad of all sections after NTG (Gr. I) were compared with those in patients who showed a decrease in (Ad-As)/Ad of all sections (Gr. II). There was no significant correlation between CAG findings in Gr. I and Gr. II. The only difference between these two groups before NTG was that mean Ad of sections in Gr. I was significantly greater than that of Gr. II. After NTG, Gr. I showed a significant decrease of BP, but Gr. II did not show any significant change. (Ad-As) of sections in Gr. I increased or showed no change after NTG, but those in Gr. II decreased. In conclusion, NTG can reverse wall motion asynergy, especially in hypokinetic segments, and produce favorable changes in pump function in patients with increased Ad before NTG. The mechanism of NTG to improve wall motion and pump function is considered to be afterload and preload reduction.

Blood Pressure↗
PubMed1982

Hypoglycemic action of 2-[2-(4,5-dihydro-1H-imidazol-2-yl)-1-phenylethyl]pyridine dihydrochloride sesquihydrate (DG-5128), a new hypoglycemic agent.

2-[2-(4,5-Dihydro-1H-imidazol-2-yl)-1-phenylethyl]pyridine dihydrochloride sesquihydrate (GD-5128) is a new hypoglycemic agent structurally unrelated to the known hypoglycemics. It was effective in reducing fasting blood glucose levels in mice, rats, dogs and monkeys at a single oral dose ranging from 5 to 25 mg/kg. DG-5128 was also effective in suppressing hyperglycemia induced by oral and subcutaneous glucose load in mice, rats and monkeys. In addition, it was interesting to find that DG-5128 effectively suppressed glucose-induced and post-prandial hyperglycemia in genetically diabetic mice of AyKK strain which were resistant to the action of tolbutamide, and that it strongly and specifically inhibited adrenaline-induced platelet aggregation. The hypoglycemic activity was not affected by simultaneous administration of other drugs including mefenamate, sulfamonomethoxine, cefazolin, dicoumarol, furosemide and clofibrate. DG-5128 did not cause lactic acidosis in rats even after repeated administration of large doses. These findings suggest usefulness of DG-5128 as a new anti-diabetic agent.

Animals↗
PubMed1981

Translocation of hepatic cytosol androgen receptor to the nucleus in vivo in male rats.

Testosterone, which was injected s.c. into adult male rats castrated 15 h prior to the injection, decreased the number of androgen-specific binding sites in the cytosol at 30 min. Coincidentally, a substantial increase was observed in the nucleus. The decreased number of the sites in the cytosol was restored to the initial level at 60 min; on the contrary, a decrease was observed in the nucleus.

Animals↗
PubMed1981

Lymph node metastases from carcinomas developing in pedunculated and semipedunculated colorectal adenomas.

Intramucosal carcinomas do not metastasise, but 5% to 10% of patients with submucosal cancers show lymph node involvement. Some of these submucosal cancers occur in pedunculated or semipedunculated polyps, which are usually treated by endoscopic polypectomy. Of 214 colorectal polyps removed endoscopically at the Keio University Hospital from 1976 to 1979, six showed submucosal invasive carcinoma. All six patients were subjected to colon resection, and two were found to have lymph node metastases. Consideration of these cases and of the literature suggests that resection is necessary after endoscopic polypectomy when there is carcinoma at the cut end, massive carcinomatous invasion of the neck of the polyp, lymphatic involvement, or poorly differentiated adenocarcinoma.

Adenocarcinoma↗